Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a
pharmaceutical company dedicated to providing solutions to unmet
medical needs by advancing androgen and metabolic therapies for men
and women, today reported financial results for the first quarter
of 2022.
“We delivered a strong first quarter, as the total number of
prescriptions written for JATENZO continued to increase,” said Dr.
Robert Dudley, President and Chief Executive Officer of Clarus.
“With the closing of our recent upsized $30 million underwritten
public offering, we intend to continue our strategic marketing
initiatives designed to increase awareness about JATENZO and fuel
its further growth. We are excited about additional patent coverage
for JATENZO and new patent coverage for CLAR-121, as we
recently received a notice of allowance for each. We also applied
for Orphan Drug Designation for CLAR-121. Our focus remains on
driving long-term stockholder value as we accomplish our business
objectives. We thank our employees for their commitment to
excellence and our stockholders for their loyalty during these
extraordinary times.”
Recent Business Highlights
- Increased total prescriptions for JATENZO in the first quarter
of 2022 sequentially and year over year by 12% and 75%,
respectively, compared to the fourth quarter of 2021 and first
quarter of 2021, driven primarily by advertising and promotion and
an increase in payer coverage across all payer channels
- Presented new data for JATENZO at the Androgen Society 4th
Annual Meeting and at the 2022 American Urological Association
Annual Meeting
- Received a notice of allowance from the U.S. Patent and
Trademark Office (USPTO) for patent claims covering JATENZO; once
issued, this will be the eighth patent for JATENZO to be listed in
the U.S. Food and Drug Administration’s (FDA’s) Orange Book
- Received a notice of allowance from the USPTO for patent claims
covering CLAR-121, a proprietary combination of testosterone and
anastrozole delivered by a subcutaneous implant for the treatment
of androgen receptor-mediated inflammatory breast disease
that predominantly affects women
- Applied for Orphan Drug Designation from the FDA for CLAR-121
for the treatment of inflammatory periductal mastitis (PDM) for
women
- Announced pricing and closing of an upsized $30 million
underwritten public offering, extending cash runway into
approximately September 2022
- Continued to explore strategic alternatives to maximize
stockholder value
First Quarter 2022 HighlightsFirst quarter 2022
net revenue increased 72% to $4.0 million from $2.3 million in the
same period last year, related to the continued growth in sales of
JATENZO.
Gross margin was 83% for the first quarter of 2022, compared to
84% for the prior year period.
First quarter 2022 operating expenses increased by 33% to $16.9
million from $12.8 million in the same period last year, primarily
attributed to an increase in sales and marketing activity
associated with the promotion of JATENZO and increases in general
and administrative expenses associated with increased headcount,
partially offset by decreased research and development
expenses.
Included in total operating expenses for first quarter 2022 was
an increase in sales and marketing expenses of 35% to $10.7 million
from $7.9 million in the same period last year, primarily
attributed to advertising and promotional spend associated with
JATENZO.
Also included in total operating expenses for first quarter 2022
was an increase in general and administrative expenses of 47%
to $5.3 million from $3.6 million in the same period last year,
primarily attributed to an increase in personnel costs associated
with a growing business and expenses associated with being a public
company.
Total operating expenses for first quarter 2022 also reflect a
decrease in research and development expenses of 27% to $0.9
million from $1.2 million in the same period last year, primarily
attributed to the timing of clinical costs associated with our lead
commercial asset.
First quarter 2022 net loss was $14.9 million, or $0.61 per
common share, compared to net loss of $15.4 million, or $0.00 per
common share, in the same period last year.
Major Upcoming Milestones
- Phase 4 clinical trial for JATENZO as testosterone therapy for
female-to-male transgender individuals (Investigator-Initiated
Study) expected to be initiated in the second half of 2022
- Phase 2 clinical trial for CLAR-121 (testosterone +
anastrozole) for the treatment of PDM expected to be initiated in
the second half of 2022, subject to availability of funding
- Phase 2 clinical trial for once daily oral testosterone
undecanoate for the treatment of male hypogonadism expected to be
initiated in the second half of 2022, subject to availability of
funding
- Phase 1 clinical trial for CLAR-222 (CoQ10 + caspofungin) for
the treatment of primary forms of CoQ10 deficiency and related
mitochondrial dysfunction expected to be initiated in the second
half of 2022, subject to availability of funding
- Results from the Phase 4 clinical trial of JATENZO for the
treatment of hypogonadal men with chronic kidney disease expected
in the first half of 2023
Conference Call and WebcastClarus will host a
conference call today at 5:15 p.m. ET to discuss the results. The
dial-in numbers are (844) 249-2007 for domestic callers and (224)
619-3902 for international callers. The conference ID number is
7677008. A live webcast and replay of the conference call will be
accessible through the Investors section of Clarus Therapeutics’
website at Investors.ClarusTherapeutics.com.
About Clarus Therapeutics Holdings, Inc.Clarus
Therapeutics Holdings, Inc. is a pharmaceutical company with
expertise in developing androgen and metabolic therapies for men
and women – including potential therapies for orphan indications.
Clarus Therapeutics’ first commercial product is JATENZO
(testosterone undecanoate). For more information, visit
www.clarustherapeutics.com and www.jatenzo.com. Follow us on
Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).
Clarus Forward-Looking StatementsCertain
statements in this press release constitute “forward-looking
statements” for purposes of the federal securities laws. The words
“anticipate,” “believe,” “contemplate,” “continue,” “could,”
“estimate,” “expect,” “intends,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions may identify forward-looking
statements, but the absence of these words does not mean that a
statement is not forward-looking. Clarus’ forward-looking
statements in this press release include, but are not limited to,
statements regarding its strategic marketing initiatives for
JATENZO, potential Orphan Drug Designation for CLAR-121,
expectations regarding Clarus’ cash runway, exploring strategic
alternatives, and the timing of initiation and data from clinical
trials for JATENZO and other product candidates, among others.
These forward-looking statements are based on current expectations
and beliefs concerning future developments and their potential
effects. There can be no assurance that future developments
affecting Clarus will be those anticipated. These forward-looking
statements involve a number of risks, uncertainties (some of which
are beyond Clarus’ control) or other assumptions that may cause
actual results or performance to be materially different from those
expressed or implied by these forward-looking statements. These
risks and uncertainties include, but are not limited to, the risks
associated with pharmaceutical development, risks associated with
Clarus’ financial position, and those factors described under the
heading “Risk Factors” in Clarus’ annual report on 10-K for the
year ended December 31, 2021, filed with the Securities and
Exchange Commission (the SEC) on March 31, 2022, and those
that are included in any of Clarus’ future filings with the SEC.
Some of these risks and uncertainties may in the future be
amplified by the ongoing COVID-19 pandemic and there may be
additional risks that Clarus considers immaterial, or which are
unknown. It is not possible to predict or identify all such risks.
Clarus’ forward-looking statements only speak as of the date they
are made, and Clarus does not undertake any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
under applicable securities laws.
JATENZO® is a registered trademark of Clarus Therapeutics
Holdings, Inc.
Clarus Contact:Kara StancellVice President,
Investor Relations & Corporate
Communicationskstancell@clarustherapeutics.com (847) 562-4300
x 206
The following presents Clarus Therapeutics Holdings, Inc.
statements of operations for the three months ended March 31, 2022
and 2021:
CLARUS THERAPEUTICS HOLDINGS,
INC.Consolidated Statements of Operations
(Unaudited)(in thousands, except share and
per share data)
|
|
Three Months EndedMarch 31, |
|
|
2022 |
|
|
2021 |
|
Revenue: |
|
|
|
|
|
|
|
|
Net product revenue |
|
$ |
4,011 |
|
|
$ |
2,330 |
|
Cost of product sales |
|
|
664 |
|
|
|
367 |
|
Gross profit |
|
|
3,347 |
|
|
|
1,963 |
|
Operating expenses: |
|
|
|
|
|
Sales and marketing |
|
|
10,729 |
|
|
|
7,937 |
|
General and administrative |
|
|
5,285 |
|
|
|
3,605 |
|
Research and development |
|
|
881 |
|
|
|
1,210 |
|
Total operating expenses |
|
|
16,895 |
|
|
|
12,752 |
|
Loss from operations |
|
|
(13,548 |
) |
|
|
(10,789 |
) |
Other (expense) income,
net: |
|
|
|
|
|
Change in fair value of warrant liability, net |
|
|
642 |
|
|
|
— |
|
Interest income |
|
|
1 |
|
|
|
— |
|
Interest expense |
|
|
(1,965 |
) |
|
|
(4,640 |
) |
Total other (expense), net |
|
|
(1,322 |
) |
|
|
(4,640 |
) |
Net loss before income
taxes |
|
|
(14,870 |
) |
|
|
(15,429 |
) |
Provision for income
taxes |
|
|
— |
|
|
|
— |
|
Net loss |
|
$ |
(14,870 |
) |
|
$ |
(15,429 |
) |
Accretion of preferred
stock |
|
|
— |
|
|
|
(3,939 |
) |
Net loss attributable to
common stockholders, basic and diluted |
|
$ |
(14,870 |
) |
|
$ |
(19,368 |
) |
Net loss per common share
attributable to common stockholders, basic and diluted |
|
$ |
(0.61 |
) |
|
|
— |
|
Weighted-average common shares
used in net loss per share attributable to common stockholders,
basic and diluted |
|
|
24,202,842 |
|
|
|
— |
|
CLARUS THERAPEUTICS HOLDINGS,
INC.Consolidated Balance
Sheets(Unaudited)(in thousands,
except share and per share data)
|
|
March 31, |
|
|
December 31, |
|
|
|
2022 |
|
|
2021 |
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
9,137 |
|
|
$ |
26,415 |
|
Accounts receivable, net |
|
|
8,005 |
|
|
|
6,341 |
|
Inventory, net |
|
|
14,930 |
|
|
|
14,214 |
|
Prepaid expenses |
|
|
4,383 |
|
|
|
4,673 |
|
Total current assets |
|
|
36,455 |
|
|
|
51,643 |
|
Property and equipment,
net |
|
|
67 |
|
|
|
65 |
|
Total assets |
|
$ |
36,522 |
|
|
$ |
51,708 |
|
Liabilities and
stockholders’ deficit |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Senior notes payable |
|
$ |
38,485 |
|
|
$ |
42,269 |
|
Accounts payable |
|
|
14,056 |
|
|
|
13,945 |
|
Accrued expenses |
|
|
11,433 |
|
|
|
8,261 |
|
Deferred revenue |
|
|
1,980 |
|
|
|
1,585 |
|
Total current liabilities |
|
|
65,954 |
|
|
|
66,060 |
|
Derivative warrant
liability |
|
|
925 |
|
|
|
1,567 |
|
Total liabilities |
|
|
66,879 |
|
|
|
67,627 |
|
Commitments and
contingencies |
|
|
|
|
|
|
Stockholders’ deficit: |
|
|
|
|
|
|
Preferred stock, $0.0001 par value; 10,000,000 shares authorized;
no shares issued and outstanding at March 31, 2022 and December 31,
2021, respectively |
|
|
— |
|
|
|
— |
|
Common stock, $0.0001 par value; 125,000,000 shares authorized;
24,750,011 and 24,025,817 shares issued and outstanding at March
31, 2022 and December 31, 2021, respectively |
|
|
2 |
|
|
|
2 |
|
Additional paid-in capital |
|
|
306,166 |
|
|
|
305,734 |
|
Accumulated deficit |
|
|
(336,525 |
) |
|
|
(321,655 |
) |
Total stockholders’ deficit |
|
|
(30,357 |
) |
|
|
(15,919 |
) |
Total liabilities and stockholders’ deficit |
|
$ |
36,522 |
|
|
$ |
51,708 |
|
Clarus Therapeutics (NASDAQ:CRXT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Clarus Therapeutics (NASDAQ:CRXT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024